Association of cytomegalovirus interstitial pneumonitis with HLA-type following allogeneic bone marrow transplantation

被引:15
作者
Yamada, S
Takatsuka, H
Takemoto, Y
Okamoto, T
Fujimori, Y
Tamura, S
Wada, H
Okada, M
Kanamaru, A
Kakisita, E
机构
[1] Hyogo Coll Med, Dept Internal Med 2, Nishinomiya, Hyogo 6638501, Japan
[2] Kinki Univ, Sch Med, Dept Internal Med 3, Osaka 589, Japan
关键词
cytomegalovirus interstitial pneumonitis; human leukocyte antigen; bone marrow transplantation; tumor necrosis factor-alpha;
D O I
10.1038/sj.bmt.1702244
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Certain human leukocyte antigens may increase the risk of cytomegalovirus interstitial pneumonitis, an important complication of bone marrow transplantation. The prevalence of this pneumonitis was compared between patients possessing either HLA-B51 or HLA-B52 and patients without either antigen. The role of tumor necrosis factor-alpha in cytomegalovirus interstitial pneumonitis was also studied. Among 72 patients undergoing allogeneic bone marrow transplantation at our institution during the past 5 years, HLA-B51 or -B52 was detected in 29, Among these 29 patients, 13 (45%) developed cytomegalovirus interstitial pneumonitis, a significantly higher rate (P < 0.001) than among patients without these HLA types (4/43, 9%), In the preconditioning and stable phases, tumor necrosis factor-alpha levels were higher in patients with HLA-B51 or HLA-B52 than in patients without (P < 0.05; t-test), Throughout the period from pre-conditioning to around day 40, except on day 0, tumor necrosis factor-alpha levels were also significantly higher (P < 0.05 to P < 0.001) in patients developing cytomegalovirus infection than in those without it. These results suggest that HLA-B51 and HLA-B52 may be risk factors for cytomegalovirus interstitial pneumonitis after bone marrow transplantation, with an increase of tumor necrosis factor-alpha also being involved.
引用
收藏
页码:861 / 865
页数:5
相关论文
共 21 条
[1]   The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice [J].
Anderson, JA ;
Lentsch, AB ;
Hadjiminas, DJ ;
Miller, FN ;
Martin, AW ;
Nakagawa, K ;
Edwards, MJ .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (08) :1952-1959
[2]   CLOSE ASSOCIATION OF HLA-B51 AND HLA-B52 IN ISRAELI PATIENTS WITH BEHCETS-SYNDROME [J].
ARBER, N ;
KLEIN, T ;
MEINER, Z ;
PRAS, E ;
WEINBERGER, A .
ANNALS OF THE RHEUMATIC DISEASES, 1991, 50 (06) :351-353
[3]   ELEVATED LEVELS OF SOLUBLE INTERCELLULAR-ADHESION MOLECULE-1 CORRELATE WITH DISEASE-ACTIVITY IN BEHCETS-DISEASE [J].
AYDINTUG, AO ;
TOKGOZ, G ;
OZORAN, K ;
DUZGUN, N ;
GURLER, A ;
TUTKAK, H .
RHEUMATOLOGY INTERNATIONAL, 1995, 15 (02) :75-78
[4]  
Ehrlich G E, 1997, Int Rev Immunol, V14, P81, DOI 10.3109/08830189709116846
[5]  
ENRIGHT H, 1993, TRANSPLANTATION, V55, P1339
[6]   THE IMMEDIATE-EARLY GENES OF HUMAN CYTOMEGALOVIRUS UP-REGULATE TUMOR-NECROSIS-FACTOR-ALPHA GENE-EXPRESSION [J].
GEIST, LJ ;
MONICK, MM ;
STINSKI, MF ;
HUNNINGHAKE, GW .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (02) :474-478
[7]   CYTOMEGALOVIRUS (CMV) ANTIGENEMIA FOR RAPID DIAGNOSIS AND MONITORING OF CMV-ASSOCIATED DISEASE AFTER BONE-MARROW TRANSPLANTATION [J].
GONDO, H ;
MINEMATSU, T ;
HARADA, M ;
AKASHI, K ;
HAYASHI, S ;
TANIGUCHI, S ;
YAMASAKI, K ;
SHIBUYA, T ;
TAKAMATSU, Y ;
TESHIMA, T ;
ETO, T ;
NAGAFUJI, K ;
MIZUNO, S ;
HOSODA, K ;
MORI, R ;
MINAMISHIMA, Y ;
NIHO, Y .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (01) :130-137
[8]   Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease [J].
Gor, D ;
Sabin, C ;
Prentice, HG ;
Vyas, N ;
Man, S ;
Griffiths, PD ;
Emery, VC .
BONE MARROW TRANSPLANTATION, 1998, 21 (06) :597-605
[9]  
GRUNDY JE, 1987, LANCET, V2, P996
[10]   Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients [J].
Humar, A ;
St Louis, P ;
Mazzulli, T ;
McGeer, A ;
Lipton, J ;
Messner, H ;
MacDonald, KS .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (02) :484-488